All In Biotech

NDA 216718 · Biogen US

Skyclarys

Omaveloxolone · Oral

NovelPriority reviewOrphan

CDER novel approval, Feb 28, 2023: To treat Friedrich's ataxia

Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Feb 28, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

20

1 Phase 3, 3 recruiting

FAERS reports

1,818

762 serious, 94 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 6, 2026.

SKYCLARYS is indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. SKYCLARYS is indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. ( 1 )

Mechanism: The precise mechanism by which omaveloxolone exerts its therapeutic effect in patients with Friedreich's ataxia is unknown. Omaveloxolone has been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 20, 2024 Supplement 8 · Efficacy OrphanLabelLetter
  • Feb 28, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • SKYCLARYS · OMAVELOXOLONE 50MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Omaveloxolone" as an intervention, any sponsor and status, largest first.

All 20 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue162
  • nausea134
  • hepatic enzyme increased130
  • product dose omission issue107
  • headache105
  • diarrhoea95
  • blood cholesterol increased86
  • muscle spasms78
  • fall76
  • atrial fibrillation69
  • alanine aminotransferase increased68
  • death63

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2023171
2024665
2025568
2026414

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Skyclarys (Omaveloxolone)

2024 spending

$101M

Beneficiaries

380

3,241 claims

Per beneficiary

$266,507

$355.92 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$44,995,927
2024$101,272,750

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 11 on PubMed

Sponsor: Biogen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.